Search the Studies

116 Studies found from all possible combinations of your search terms. Select a protocol that you wish to review.
Protocol Number Title Protocol Status Min-Max Age Institute Keywords
001784-CPhase 1/2 Study of Donor-Derived Anti-CD33 Chimeric Antigen Receptor Expressing T Cells (VCAR33) in Patients with Relapsed or Refractory Acute Myeloid Leukemia After Allogeneic Hematopoietic Cell TransplantationRecruitment has not started18-120 YearsNCI Acute Leukemia
001620-CPilot Prospective Study for PET-CT Imaging in Participants with Relapsed/Refractory Acute LeukemiasParticipants currently recruited/enrolled5-39 YearsNCI Acute Leukemia
001554-CPhase I/II Trial of Pacritinib, a Kinase Inhibitor of CSF1R, IRAK1, JAK2, and FLT3, in Adults and Pediatric Participants 12 Years of Age or Older with Myelodysplastic Syndromes or Myelodysplastic/Myeloproliferative NeoplasmsRecruitment has not started12-120 YearsNCI Acute Leukemia
001541-CA Phase I/II Trial of Eltanexor (KPT-8602) with Inqovi (Decitabine-Cedazuridine) in High-Risk Myelodysplastic SyndromesParticipants currently recruited/enrolled18-120 YearsNCI Acute Leukemia
000975-CCollection of Blood, Bone Marrow, Skin, Saliva, and Stool Samples from Healthy Volunteers Used for Comparative Analysis of Myeloid MalignanciesParticipants currently recruited/enrolled18-125 YearsNCI Acute Leukemia
000867-CCHumanitarian Use Device (HUD) Protocol for Use of Miltenyi CliniMACS (Registered Trademark) CD34 Reagent System in AMLParticipants currently recruited/enrolled0-125 YearsCC Acute Leukemia
000792-CA Pilot Trial to Evaluate Next-Generation Sequencing (NGS) Testing and Monitoring of B-Cell Recovery to Guide Management Following CAR T-cell Induced Remission in Pediatric Patients with B Lineage Acute Lymphoblastic LeukemiaParticipants currently recruited/enrolled1-25 YearsNCI Acute Leukemia
000732-CA Long-Term Follow-Up Study of Patients Who Received VOR33Participants currently recruited/enrolled18-125 YearsNCI Acute Leukemia
000731-CA First-In-Human, Open-Label, Multicenter Study of VOR33 in Patients with Acute Myeloid Leukemia who are at High-Risk for Leukemia Relapse following Hematopoietic Cell TransplantationParticipants currently recruited/enrolled18-70 YearsNCI Acute Leukemia
000661-CComprehensive Molecular and Clinical Evaluation of Pediatric and Adult MDSParticipants currently recruited/enrolled0-120 YearsNCI Acute Leukemia
000613-CPhase I/II Trial to Determine the Lowest Effective Dose of Post-Transplantation Cyclophosphamide in Combination with Sirolimus and Mycophenolate Mofetil as Graft-Versus-Host Disease Prophylaxis after Reduced Intensity Conditioning and Peripheral Blood StParticipants currently recruited/enrolled12-125 YearsNCI Acute Leukemia
000324-CPhase 1/2 Dose Escalation Study of CD19/CD22 Bicistronic Chimeric Antigen Receptor (CAR) T Cells in Children and Young Adults with Recurrent or Refractory CD19/CD22-expressing B Cell MalignanciesParticipants currently recruited/enrolled3-39 YearsNCI Acute Leukemia
000067-CUnderstanding the Patient Experience: Symptom Burden in Pediatric Patients Receiving Chimeric Antigen Receptor (CAR) T-cell TherapyCompleted Study; data analyses ongoing2-125 YearsNCI Acute Leukemia
20-C-0028Phase 1/2 Study of Anti-CD33 Chimeric Antigen Receptor-Expressing T Cells (CD33CART) in Children and Young Adults with Relapsed/Refractory Acute Myeloid LeukemiaParticipants currently recruited/enrolled3-35 YearsNCI Acute Leukemia
19-HG-0059Longitudinal Studies of Patients and Families with Familial Platelet Disorders with Associated Myeloid Malignancy (FPDMM) Caused by RUNX1 Germline Variants or FPDMM-Like ConditionsParticipants currently recruited/enrolled0-125 YearsNHGRIAcute Leukemia
18-C-0059Phase 1 Dose Escalation Study of CD19/CD22 Chimeric Antigen Receptor (CAR) T Cells in Children and Young Adults with Recurrent or Refractory CD19/CD22-expressing B Cell MalignanciesParticipants currently recruited/enrolled3-39 YearsNCI Acute Leukemia
17-C-0137Leukapheresis for CAR or Adoptive Cell Therapy ManufacturingEnrolling by Invitation3-65 YearsNCI Acute Leukemia
17-C-0028A Pilot Study of Vincristine Sulfate Liposome Injection (Marqibo ) in Combination with Chemotherapy for Children, Adolescents, and Young Adults with Relapse of Acute Lymphoblastic LeukemiaCompleted Study; data analyses ongoing2-21 YearsNCI Acute Leukemia
15-C-0093Phase I Trial of TURALIO (pexidartinib, PLX3397) in Children and Young Adults with Refractory Leukemias and Refractory Solid Tumors Including Neurofibromatosis Type 1 (NF1) Associated Plexiform Neurofibromas (PN) and Tenosynovial Giant Cell Tumor (TGCTParticipants currently recruited/enrolled3-35 YearsNCI Acute Leukemia
15-C-0067A Phase I/II Open Label, Dose Escalation Study of Palifermin (Kepivance) in Persons Undergoing Unrelated Donor Allogeneic Hematopoietic Cell TransplantationParticipants currently recruited/enrolled18-125 YearsNCI Acute Leukemia
15-C-0029Phase I Dose Escalation Study of Anti-CD22 Chimeric Receptor T Cells in Pediatric and Young Adults with Recurrent or Refractory CD22-expressing B Cell MalignanciesNo longer recruiting/follow-up only3-39 YearsNCI Acute Leukemia
14-C-0004A Multicenter Phase 2 Study of the Bruton's Tyrosine Kinase Inhibitor PCI-32765 (Ibrutinib) for Treatment of Relapsed Hairy Cell LeukemiaNo longer recruiting/follow-up only18-125 YearsNCI Acute Leukemia
11-C-0136Multi-Institutional Prospective Pilot Study of Lupron to Enhance Lymphocyte Immune Reconstitution Following Allogeneic Bone Marrow Transplantation in Post-Pubertal Children and Adults with Molecular Imaging EvaluationCompleted Study; data analyses ongoing2-120 YearsNCI Acute Leukemia
07-C-0195Phase II Trial of Targeted Immune-Depleting Chemotherapy and Reduced-Intensity Allogeneic Hematopoietic Stem Cell Transplantation Using 8/8 and 7/8 HLA-matched Unrelated Donors and Utilizing Two Graft-versus-Host Disease Prophylaxis Regimens for the TreaCompleted Study; data analyses ongoing18-74 YearsNCI Acute Leukemia
04-C-0102Hematologic Malignancy Biology StudyEnrolling by Invitation1-75 YearsNCI Acute Leukemia
99-H-0050Non-Myeloablative Allogeneic Peripheral Blood Mobilized Hematopoietic Precursor Cell Transplantation for Hematologic Malignancies in High Risk Patients and in Patients with Debilitating Hematologic DiseasesCompleted Study; data analyses ongoing2-80 YearsNHLBIAcute Leukemia
002029-CA Phase 2 Study of Venetoclax in Relapsed Classic or Variant Hairy Cell LeukemiaRecruitment has not started0-0 YearsNCI Leukemia
001599-CPhase I/II Trial of Anti-CD19 Chimeric Antigen Receptor T-Cell Immunotherapy for Chronic Lymphocytic Leukemia (CLL)Recruitment has not started18-120 YearsNCI Leukemia
001528-HA Phase I/II, Intra-Patient Dose-Escalation Study of the Selective GlyT1 Inhibitor, Bitopertin for Steroid-Refractory Diamond-Blackfan Anemia.Participants currently recruited/enrolled18-100 YearsNHLBIErythroid
001524-CA Phase I Trial of Anti-CD19 and Anti-CD20 Bicistronic Chimeric Antigen Receptor T- Cells for Treating B-cell MalignanciesParticipants currently recruited/enrolled18-75 YearsNCI Leukemia
001066-DAOrexin's Role in The Neurobiology of Substance Use DisorderParticipants currently recruited/enrolled18-60 YearsNIDA Acute
000923-HObservational Study of Cardiac Arrhythmias During Treatment with BTK Inhibitors or VenetoclaxParticipants currently recruited/enrolled18-110 YearsNHLBILeukemia
000715-CHBiorepository in Participants Who Undergo OTC for Gonadotoxic TherapyParticipants currently recruited/enrolled4-35 YearsNICHDAcute
000686-CHIntrathecal 2-Hydroxypropyl-Beta-Cyclodextrin for Neurological Decline in Patients with Niemann-Pick Disease Type C1Participants currently recruited/enrolled18-125 YearsNICHDAcute
000631-CInvestigation of the Cognitive Aftereffects of Neurotoxicity in Children and Young Adults with Relapsed/Refractory Hematologic Malignancies who Receive CAR T-cell TherapyClinical hold/Recruitment or enrollment suspended5-125 YearsNCI Leukemia
000509-CAn Open Label, Multi-Center Roll-Over Study to Assess Long-Term Safety in Patients Who are Ongoing or Have Completed a Prior Global Novartis or GSK Sponsored Tafinlar (Dabrafenib) and/or Mekinist (Trametinib) Study and are Judged by the Investigator to BEnrolling by Invitation18-125 YearsNCI Leukemia
000489-CPhase I/II Study Using Prophylactic Donor Lymphocyte Infusion Early Post-Transplant After Allogeneic Hematopoietic Cell Transplantation Using Post-Transplantation Cyclophosphamide for High-Risk Hematologic MalignanciesParticipants currently recruited/enrolled12-120 YearsNCI Leukemia
000464-HEvaluation of Clonal Hematopoiesis in Patients with Sickle Cell Disease Receiving Curative TherapiesEnrolling by Invitation4-125 YearsNHLBILeukemia
000444-HVaccine Responses in Patients with B Cell MalignanciesParticipants currently recruited/enrolled18-90 YearsNHLBILeukemia
000326-HA Phase 1, Dose Escalation, Safety and Tolerability Study of NX- 2127, a Bruton's Tyrosine Kinase (BTK) Degrader, in Adults with Relapsed/Refractory B-cell MalignanciesParticipants currently recruited/enrolled18-125 YearsNHLBILeukemia
000207-ARThe Natural History of Coronavirus Disease (COVID-19) in Systemic Autoimmune Diseases; An Observational Prospective StudyParticipants currently recruited/enrolled15-125 YearsNIAMSAcute
000115-CA Trial of the Safety and Immunogenicity of the COVID-19 Vaccine (mRNA-1273) in Participants with Hematologic Malignancies and Various Regimens of Immunosuppression, and in Participants with Solid Tumors on PD1/PDL1 Inhibitor Therapy, Including Booster DCompleted Study; data analyses ongoing18-125 YearsNCI Leukemia
000049-HEvaluation of the Safety,Tolerability, Pharmacokinetics, and Pharmacodynamics of Long-term Mitapivat Dosing in Subjects with Stable Sickle Cell Disease: An Extension of a Phase I Pilot Study of MitapivatNo longer recruiting/follow-up only18-70 YearsNHLBIAcute
21-C-0019Phase I Study of Anti-CD22 Chimeric Receptor T Cells in Patients with Relapsed/Refractory Hairy Cell Leukemia and VariantParticipants currently recruited/enrolled18-125 YearsNCI Leukemia
20-I-0111COVID-19-associated Lymphopenia Pathogenesis Study in BloodParticipants currently recruited/enrolled18-125 YearsNIAIDAcute
20-HG-0120Acute Infection in Mitochondrial Disease: An Observational Prospective Natural History Study of Metabolism, Infection and ImmunityParticipants currently recruited/enrolled0-125 YearsNHGRIAcute
20-H-0049NHLBI DIR Cardiovascular Branch PK Papyrus Covered Stent Ethics Oversight of Humanitarian Use Device for Treatment of Acute Perforations of Native Coronary Arteries and Coronary Bypass Grafts in Vessels 2.5 to 5.0 mm in DiameterEnrolling by Invitation18-125 YearsNHLBIAcute
20-H-0021Treatment of Refractory Diamond-Blackfan Anemia with EltrombopagCompleted Study; data analyses ongoing2-99 YearsNHLBIErythroid
20-CC-0113Cardiopulmonary Inflammation and Multi-System Imaging During the Clinical Course of COVID-19 Infection in Asymptomatic and Symptomatic Persons (COVID ARC 19)Completed Study; data analyses ongoing18-80 YearsCC Acute
20-C-0162A Phase 1 Study of Venetoclax with Obinutuzumab and Magrolimab (VENOM) in Relapsed and Refractory Indolent B-cell MalignanciesCompleted Study; data analyses ongoing18-125 YearsNCI Leukemia
20-C-0103Investigation of the B- and T-cell Repertoire and Immune Response in Patients with Acute and Resolved COVID-19 InfectionNo longer recruiting/follow-up only18-125 YearsNCI Acute
20-C-0076Phase 2 Trial of Encorafenib plus Binimetinib for Patients with BRAF V600 Mutated Relapsed/Refractory HCLParticipants currently recruited/enrolled18-125 YearsNCI Leukemia
20-C-0075Phase 2 Trial for Binimetinib for Patients with Relapsed/Refractory BRAF Wild Type Hairy Cell Leukemia and VariantParticipants currently recruited/enrolled18-125 YearsNCI Leukemia
20-C-0011Phase 1 Study of Recombinant Human IL-15 (rhIL-15) and Mogamulizumab for Patients with Refractory or Relapsed Adult T-Cell Leukemia and Mycosis Fungoides/Sezary SyndromeCompleted Study; data analyses ongoing18-125 YearsNCI Leukemia
20-AA-0057The Effect of Acute Alcohol Intoxication on Neural Processes During Decisions to Engage in HIV Risk BehaviorsParticipants currently recruited/enrolled21-65 YearsNIAAAAcute
19-H-0111Early Clonal Dynamics During Venetoclax Treatment for Chronic Lymphocytic Leukemia (CLL)Participants currently recruited/enrolled18-125 YearsNHLBILeukemia
19-H-0097A Pilot Study to Evaluate the Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of Escalating Multiple Oral Doses of AG-348 in Subjects with Stable Sickle Cell DiseaseCompleted Study; data analyses ongoing18-70 YearsNHLBIAcute
19-H-0001Response to the SHINGRIX Varicella Zoster Virus (VZV) Vaccine in Chronic Lymphocytic Leukemia (CLL) Patients that are Treatment Na(SqrRoot) ve or Receiving Bruton s-tyrosine Kinase Inhibitor (BTK-I) TherapyCompleted Study; data analyses ongoing18-100 YearsNHLBILeukemia
19-C-0112Phase I/II Study De-intensifying Exposure of Post-transplantation Cyclophosphamide as GVHD Prophylaxis after HLA-haploidentical Hematopoietic Cell Transplantation for Hematologic MalignanciesParticipants currently recruited/enrolled12-120 YearsNCI Leukemia
19-C-0042A Phase I Study of Moxetumomab Pasudotox-tdfk (Lumoxiti (TM)) and either Rituximab (Rituxan (R)) or Ruxience for Relapsed Hairy Cell LeukemiaNo longer recruiting/follow-up only18-125 YearsNCI Leukemia
18-DA-N042Understanding the Acute Modulation of Brain Activity by Transcranial Magnetic StimulationParticipants currently recruited/enrolled18-60 YearsNIDA Acute
18-C-0080Feasibility and Preliminary Efficacy of an Enhanced Mindfulness Intervention for Children and Young Adults with High Grade or High-Risk Cancer and Their Caregivers: A Pilot Randomized Controlled TrialCompleted Study; data analyses ongoing5-125 YearsNCI Leukemia
17-M-0060Neuropharmacologic Imaging and Biomarker Assessments of Response to Acute and Repeated-Dosed Ketamine Infusions in Major Depressive DisorderParticipants currently recruited/enrolled18-65 YearsNIMH Acute
17-H-0118A Phase II Study Of Ibrutinib, Fludarabine, and Pembrolizumab in High-Risk or Relapsed/Refractory Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma (CLL/SLL)No longer recruiting/follow-up only18-100 YearsNHLBILeukemia
17-H-0056Pathophysiology of Acute Pain in Patients with Sickle Cell DiseaseCompleted Study; data analyses ongoing18-80 YearsNHLBIAcute
16-N-0114The Effect of Corticosteroids on Inflammation at the Edge of Acute Multiple Sclerosis Plaques: An Investigator-Blinded StudyParticipants currently recruited/enrolled18-120 YearsNINDSAcute
16-I-0078Microbial, Immune, and Metabolic Perturbations by Antibiotics (MIME study)Participants currently recruited/enrolled18-49 YearsNIAIDAcute
16-C-0061Biospecimen Procurement for Center for Immuno-Oncology Immunotherapy ProtocolsParticipants currently recruited/enrolled18-120 YearsNCI Leukemia
15-I-0056Collection of Plasma from Subjects that Recovered From or Were Vaccinated To Emerging Infectious DiseasesEnrolling by Invitation18-70 YearsNIAIDAcute
15-H-0172A Pilot Phase II Study Using Ibrutinib and Short-Course Fludarabine in Previously Untreated Patients with Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma (CLL/SLL)No longer recruiting/follow-up only18-125 YearsNHLBILeukemia
15-H-0016A Phase II Study Using ACP-196 in Patients with Relapsed/Refractory and Treatment Naive Deletion 17p CLL/SLL: Pharmacodynamic Assessment of BTK Inhibition and Anti-Tumor Response.No longer recruiting/follow-up only18-125 YearsNHLBILeukemia
15-CC-0091Pulmonary Effects of Bronchial Segmental Endotoxin Instillation in HumansClinical hold/Recruitment or enrollment suspended18-45 YearsCC Acute
15-C-0141Gene Therapy Follow up Protocol for Subjects Previously Enrolled in CAR T-Cell StudiesEnrolling by Invitation18-125 YearsNCI Leukemia
14-DK-0195Acute Effects of Canagliflozin, a Sodium Glucose Co-Transporter 2 (SGLT2) Inhibitor on Bone Metabolism in Healthy VolunteersCompleted Study; data analyses ongoing18-125 YearsNIDDKAcute
13-I-0157The Natural History of GATA2 Deficiency and Related DisordersParticipants currently recruited/enrolled2-100 YearsNIAIDLeukemia
13-H-0116A Multicenter Safety Study of Unlicensed, Investigational Cryopreserved Cord Blood Units (CBUs) Manufactured by the National Cord Blood Program (NCBP) and Provided for Unrelated Hematopoietic Stem Cell Transplantation of Pediatric and Adult PatientsParticipants currently recruited/enrolled4-125 YearsNHLBILeukemia
13-C-0132Allogeneic Hematopoietic Stem Cell Transplant for Patients with Mutations in GATA2 or the MonoMAC SyndromeParticipants currently recruited/enrolled8-70 YearsNCI Leukemia
12-H-0035A Phase II study of Ibrutinib for Patients with Chronic Lymphocytic Leukemia (CLL) or Small Lymphocytic Lymphoma (SLL) Who Need Therapy and are Older than 65 or have a 17p DeletionNo longer recruiting/follow-up only18-125 YearsNHLBILeukemia
12-DA-N474Identifying Neurobiological Mechanisms that Underlie Acute Nicotine Withdrawal and Drive Early Relapse in SmokersCompleted Study; data analyses ongoing18-65 YearsNIDA Acute
12-C-0193Lymphoid Malignancies and Precursors: Tissue Acquisition ProtocolParticipants currently recruited/enrolled18-125 YearsNCI Leukemia
11-I-0007Lentiviral Gene Transfer for Treatment of Children Older Than 2 Years of Age with X-Linked Severe Combined ImmunodeficiencyParticipants currently recruited/enrolled2-40 YearsNIAIDLeukemia
11-C-0255Clinical, Epidemiologic, and Genetic Studies of Li-Fraumeni SyndromeParticipants currently recruited/enrolled0-125 YearsNCI Leukemia
11-C-0242Collection of Blood from Patients with Cancer, Other Tumors, or Tumor Predisposition Syndromes for Analysis of Genetic Differences in Drug DispositionParticipants currently recruited/enrolled3-125 YearsNCI Leukemia
10-N-0122Evaluation, Pathogenesis, and Outcome of Subjects with or Suspected Traumatic Brain InjuryCompleted Study; data analyses ongoing18-125 YearsNINDSAcute
10-N-0012Screening Protocol for Patients with StrokeParticipants currently recruited/enrolled18-90 YearsNINDSAcute
10-I-0197Admission and Management of Occupational or Other Exposures to Biodefense/Bioterrorism Agents or to Epidemic/Emerging Infectious DiseasesParticipants currently recruited/enrolled2-99 YearsNIAIDAcute
10-H-0141A Phase II Study of Ofatumumab-Based Induction Chemoimmunotherapy Followed by Consolidation Ofatumumab Immunotherapy in Previously Untreated Patients with Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma.Completed Study; data analyses ongoing18-99 YearsNHLBILeukemia
10-CC-0150Effects of Rapid-Resisted Exercise on Ambulatory Adults with Traumatic Brain InjuryCompleted Study; data analyses ongoing18-44 YearsCC Acute
10-CC-0118Long Term Clinical Correlates of TBI: Imaging, Biomarkers, and Clinical Phenotyping ParametersClinical hold/Recruitment or enrollment suspended18-125 YearsCC Acute
10-C-0086Comprehensive Omics Analysis of Pediatric Solid Tumors and Establishment of a Repository for Related Biological StudiesParticipants currently recruited/enrolled0-125 YearsNCI Leukemia
10-C-0066A Study of Hairy Cell and other Leukemias with a Focus on Recombinant Immunotoxins for Cancer TreatmentParticipants currently recruited/enrolled18-125 YearsNCI Leukemia
10-C-0054Administration of Anti-CD19-Chimeric-Antigen-Receptor-Transduced T Cells from the Original Transplant Donor to Patients with Recurrent or Persistent B-Cell Malignancies After Allogeneic Stem Cell TransplantationCompleted Study; data analyses ongoing18-75 YearsNCI Leukemia
10-C-0025Randomized Phase II Trial of Rituximab with Either Pentostatin or Bendamustine for Multiply Relapsed or Refractory Hairy Cell LeukemiaNo longer recruiting/follow-up only18-125 YearsNCI Leukemia
09-I-0184Studies in the Pathogenesis of Systemic Capillary Leak SyndromeCompleted Study; data analyses ongoing0-100 YearsNIAIDAcute
09-I-0126Pathogenesis and Genetic Basis of Physical Induced Urticarial SyndromesCompleted Study; data analyses ongoing2-90 YearsNIAIDAcute
09-C-0053Autologous and Related/Unrelated Allogeneic Hematopoietic Stem Cell Transplant and Cellular Therapies Data Submission and Research Sample Collection to the Center for International Blood and Marrow Transplant Research (CIBMTR) and the National Marrow DonEnrolling by Invitation1-125 YearsNCI Leukemia
09-C-0005Randomized Trial of Cladribine (CdA) with Simultaneous or Delayed Rituximab to Eliminate Hairy Cell Leukemia Minimal Residual DiseaseNo longer recruiting/follow-up only18-125 YearsNCI Leukemia
08-H-0186Safety and the Anti- Tumor Effects of Escalating Doses of Adoptively Infused Ex Vivo Expanded Autologous Natural Killer (NK) Cells Against Metastatic Cancers or Hematological Malignancies Sensitized to NK-TRAIL Cytotoxicity with BortezomibCompleted Study; data analyses ongoing18-70 YearsNHLBILeukemia
08-H-0105Natural History Study of Monoclonal B Cell Lymphocytosis (MBL), Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma (CLL/SLL), Lymphoplasmacytic Lymphoma (LPL)/Waldenstrom Macroglobulinemia (WM), and Splenic Marginal Zone Lymphoma (SMZL)Participants currently recruited/enrolled18-110 YearsNHLBILeukemia
06-H-0190Treatment of T-Large Granular Lymphocyte (T-LGL) Lymphoproliferative Disorders with Alemtuzumab (Campath)Completed Study; data analyses ongoing18-85 YearsNHLBILeukemia
05-H-0130Long-Term Evaluation and Follow Up Care of Patients Treated with Allogeneic Stem Cell TransplantsParticipants currently recruited/enrolled7-80 YearsNHLBILeukemia
04-H-0161Studies of the Natural History of Sickle Cell DiseaseParticipants currently recruited/enrolled2-90 YearsNHLBIAcute
02-I-0286Efficacy of Tyrosine Kinase Inhibition in Reducing Eosinophilia in Patients with Myeloid and/or Steroid-Refractory Hypereosinophilic SyndromeParticipants currently recruited/enrolled2-125 YearsNIAIDLeukemia
02-I-0202Leukapheresis Procedures to Obtain Plasma and Lymphocytes for Research Studies on Antiretroviral-Naive HIV-Infected PatientsParticipants currently recruited/enrolled18-120 YearsNIAIDAcute
02-I-0110Natural History of Anthrax: A Study of Primary Infected, Recovered, and Exposed (SPoRE) Individuals and Evaluation of AVA Vaccinated RecipientsParticipants currently recruited/enrolled3-100 YearsNIAIDAcute
02-H-0250A Phase I/II Study of HLA-matched Mobilized Peripheral Blood Hematopoietic Stem Cell Transplantation for Advanced Mycosis Fungoides/Sezary Syndrome Using Nonmyeloablative Conditioning with Campath-1HCompleted Study; data analyses ongoing18-100 YearsNHLBILeukemia
02-CC-0266Acute Cardiac Allograft Cellular Rejection and Cardiac Allograft Vasculopathy: Identification of Diagnostic Biomarkers and Target Pathways for Preventive TherapyCompleted Study; data analyses ongoing18-100 YearsCC Acute
02-C-0210Clinical, Laboratory, and Epidemiologic Characterization of Individuals and Families at High Risk of Blood and Lymph Node MalignancyNo longer recruiting/follow-up only0-125 YearsNCI Leukemia
01-N-0007Evaluation, Pathogenesis, and Treatment of Patients with or at Risk for Cerebrovascular Disease (A Natural History/Disease Pathogenesis Protocol)Participants currently recruited/enrolled18-125 YearsNINDSAcute
00-DK-0107Search for Novel Methods to Detect Acute Renal FailureParticipants currently recruited/enrolled3-125 YearsNIDDKAcute
99-I-0084Studies of Human Pneumocystis InfectionParticipants currently recruited/enrolled3-99 YearsNIAIDAcute
98-N-0047Immuno-Virological Evaluation of Human T Cell Leukemia Virus Type-1 Associated Myelopathy (HAM/TSP)Participants currently recruited/enrolled18-120 YearsNINDSLeukemia
96-H-0049Use of Granulocyte Colony Stimulating Factor (G-CSF) Mobilized Leukapheresis Collections from Healthy Volunteers to Develop Improved Methods of Stem Cell and Lymphocyte Selection for Allogeneic TransplantationParticipants currently recruited/enrolled18-60 YearsNHLBILeukemia
94-C-0074Treatment and Natural History Study of Lymphomatoid GranulomatosisNo longer recruiting/follow-up only12-125 YearsNCI Leukemia
93-I-0086Evaluation and Long-Term Follow-Up of Patients with Acute or Chronic Inflammatory DisordersEnrolling by Invitation2-125 YearsNIAIDAcute
91-DK-0214Evaluation of Patients with Liver DiseaseParticipants currently recruited/enrolled2-100 YearsNIDDKAcute
10 Center Drive,Bethesda, MD 20892 | Directions
Privacy Statement | Accessibility | Plain Language | FOIA | Disclaimer
Clinical Center | National Institutes of Health | HHS Vulnerability Disclosure | U.S. Department of Health and Human Services | USA.gov
NIH…Turning Discovery Into Health®